Materials of Construction Based on Recovery Data for Cleaning Validation - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Materials of Construction Based on Recovery Data for Cleaning Validation
The material of construction is a factor in the recovery of residue in cleaning validation. An analysis of existing recovery data showed that recovery factors for drug products on various materials of construction may be categorized into several groupings.


Pharmaceutical Technology


3. G.M. Chudzik, "General Guide to Recovery Studies Using Swab Sampling Methods for Cleaning Validation," J. Val. Technol. 5 (1), 77–81 (1999).

4. R. Sharnez et al., "In Situ Monitoring of Soil Dissolution Dynamics: A Rapid and Simple Method for Determining Worst-case Soils for Cleaning Validation," PDA J. Pharm. Sci. and Technol., 58 (4), 203–214 (2004).

5. C. Glover, "Validation of the Total Organic Carbon (TOC) Swab Sampling and Test Method," PDA J. Pharm. Sci. and Technol. 60 (5), 284–290 (2006).


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
Which of the following business challenge poses the greatest threat to your company?
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
Building a sustainable pipeline of products
21%
Attracting a skilled workforce
29%
Obtaining/maintaining adequate financing
8%
Regulatory compliance
42%
View Results
Eric Langer Outsourcing Outlook Eric LangerBiopharma Outsourcing Activities Update
Cynthia Challener, PhD Ingredients Insider Cynthia Challener, PhDAppropriate Process Design Critical for Commercial Manufacture of Highly Potent APIs
Jill Wechsler Regulatory Watch Jill Wechsler FDA and Manufacturers Seek a More Secure Drug Supply Chain
Sean Milmo European Regulatory WatcchSean MilmoQuality by Design?Bridging the Gap between Concept and Implementation
Medicare Payment Data Raises Questions About Drug Costs
FDA Wants You!
A New Strategy to Tackle Antibiotic Resistance
Drug-Diagnostic Development Stymied by Payer Concerns
Obama Administration Halts Attack on Medicare Drug Plans
Source: Pharmaceutical Technology,
Click here